IRulya Therapeutics Inc. Common Stock
IRLA
86 hedge funds and large institutions have $673M invested in IRulya Therapeutics Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 23 increasing their positions, 25 reducing their positions, and 11 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
37% more capital invested
Capital invested by funds: $491M → $673M (+$183M)
18% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 11
3.51% more ownership
Funds ownership: 59.86% → 63.37% (+3.5%)
2% more funds holding
Funds holding: 84 → 86 (+2)
8% less call options, than puts
Call options by funds: $16.2M | Put options by funds: $17.6M
8% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$25.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$8.68M |
| 3 |
ECG
EPIQ Capital Group
San Francisco,
California
|
+$5.35M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$5.04M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$4.27M |
| 3 |
Millennium Management
New York
|
-$3.5M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.75M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$1.48M |
IRLA Hedge Fund Activity: Q1 2021 in Review
86 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in IRulya Therapeutics Inc. Common Stock (IRLA) for Q1 2021, worth a combined $673M — up 37% from $491M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new IRLA positions and 11 closed out — a net gain of 2 holders — while 23 added to existing stakes and 25 trimmed.
The largest buyer was Capital World Investors, adding an estimated $25.7M. The largest seller was Morgan Stanley, cutting an estimated $5.04M.
- 86 institutional investors held IRulya Therapeutics Inc. Common Stock (IRLA) as of Q1 2021, up from 84 in Q4 2020.
- Funds reported $673M of IRulya Therapeutics Inc. Common Stock stock for Q1 2021, up 37% quarter-over-quarter.
- 13 funds opened new IRulya Therapeutics Inc. Common Stock positions in Q1 2021 and 11 closed out, a net change of +2 holders.
- The largest IRulya Therapeutics Inc. Common Stock buyer in Q1 2021 was Capital World Investors, an estimated $25.7M added.
- The largest IRulya Therapeutics Inc. Common Stock seller in Q1 2021 was Morgan Stanley, an estimated $5.04M sold.
Based on aggregated 13F filings for Q1 2021.